Phase I Study of OPC-61815

NCT03510663 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Congestive Heart Failure

Interventions

DRUG: OPC-61815 16mg
DRUG: OPC-61815 32mg
DRUG: Moxifloxacin
DRUG: Placebos

Sponsor

Otsuka Pharmaceutical Co., Ltd.